Reata Pharmaceuticals Inc Revenue Growth Rates (RETA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Reata Pharmaceuticals Inc   (NASDAQ: RETA)
 

RETA's Revenue Growth by Quarter and Year

Reata Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RETA Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 22.75
1st Quarter March 0.20
FY 22.95

RETAs Annual Revenue
Reata Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 2.22 millions
Reata Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 11.49 millions
Reata Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 9.02 millions
Reata Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 26.52 millions
Reata Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 53.59 millions




RETA Revenue second quarter 2023 Y/Y Growth Comment
Reata Pharmaceuticals Inc achieved in the second quarter 2023, above Company average Revenue surge of 2892.89% year on year, to $ 22.75 millions.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 7 other companies have achieved higher Revenue growth. While Reata Pharmaceuticals Inc ' s Revenue doubling of 2892.89% ranks overall at the positon no. 42 in the second quarter 2023.


RETA Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - - -70.85 % 19.48 %
3rd Quarter September - -92.69 % 427.86 % -83.01 %
2nd Quarter June 2892.89 % -65.77 % -27.69 % -60.79 %
1st Quarter March -78.02 % -3.19 % -30.37 % -82.63 %
FY   - -80.75 % 27.41 % -

Financial Statements
Reata Pharmaceuticals Inc 's second quarter 2023 Revenue $ 22.75 millions RETA's Income Statement
Reata Pharmaceuticals Inc 's second quarter 2022 Revenue $ 0.76 millions Quarterly RETA's Income Statement


RETA Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - -87.42 % 127.86 %
3rd Quarter September - -28.95 % 232.88 % -54.4 %
2nd Quarter June 11273 % -16.48 % 136.17 % 127.41 %
1st Quarter March - -2.15 % -70.53 % -49.44 %
FY (Year on Year)   - -80.75 % 27.41 % -


Back to RETA Growth rate Comparisons >> Back to RETA Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #8
Healthcare Sector #11
Overall #42

Revenue Y/Y Growth Statistics
High Average Low
2885.04 % 85.74 % -100 %
(Jun 30 2023)   (Dec 31 2022)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #8
Healthcare Sector #11
Overall #42
Revenue Y/Y Growth Statistics
High Average Low
2885.04 % 85.74 % -100 %
(Jun 30 2023)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Reata Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11564.62 % 473.93 % -100 %
(Jun 30 2023)  


RETA's II. Quarter Q/Q Revenue Comment
Reata Pharmaceuticals Inc achieved in the II. Quarter 2023 above company average sequential Revenue doubling of 11273%, to $ 22.75 millions, from $0.20 millions in the first quarter.
RETA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry Reata Pharmaceuticals Inc achieved highest sequential Revenue growth. While Reata Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #3
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #3
Revenue Q/Q Growth Statistics
High Average Low
11564.62 % 473.93 % -100 %
(Jun 30 2023)  


RETA's II. Quarter Q/Q Revenue Comment
Reata Pharmaceuticals Inc achieved in the II. Quarter 2023 above company average sequential Revenue doubling of 11273%, to $ 22.75 millions, from $0.20 millions in the first quarter.
RETA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry Reata Pharmaceuticals Inc achieved highest sequential Revenue growth. While Reata Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3.


Reata Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 3.15 $ 10.00
Y / Y Revenue Growth (TTM) - - - -77.09 % 28.91 %
Year on Year Revenue Growth Overall Ranking # 717 # 335 # 422 # 2826 # 521
Seqeuential Revenue Change (TTM) - - - -68.5 % -12.73 %
Seq. Revenue Growth (TTM) Overall Ranking # 3188 # 2277 # 2803 # 3261 # 1993


Cumulative Revenue growth Comment
Reata Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2023, compare to Revenue of $ 10 millions a year ago.

In the Healthcare sector 166 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 335 to 717.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 167
Healthcare Sector # 167
Overall # 717

Revenue TTM Y/Y Growth Statistics
High Average Low
69.25 %
 -20.65 %
-74.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 167
Sector # 461
S&P 500 # 3188
Cumulative Revenue growth Comment
Reata Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2023, compare to Revenue of $ 10 millions a year ago.

In the Healthcare sector 166 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 335 to 717.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 167
Healthcare Sector # 167
Overall # 717

Revenue TTM Y/Y Growth Statistics
High Average Low
69.25 %
-20.65 %
-74.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 167
Sector # 461
S&P 500 # 3188




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RETA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Repare Therapeutics Inc 4,354.93%$ 4,354.934 millions
Sunshine Biopharma Inc 3,599.67%$ 3,599.671 millions
Reata Pharmaceuticals Inc 2,885.04%$ 2,885.039 millions
Tg Therapeutics Inc 2,606.06%$ 2,606.061 millions
Seelos Therapeutics inc 2,105.26%$ 2,105.263 millions
Neuroone Medical Technologies Corp1,865.45%$ 1,865.447 millions
Catheter Precision Inc 1,820.00%$ 1,820.000 millions
Cardio Diagnostics Holdings Inc 1,715.79%$ 1,715.789 millions
Inhibikase Therapeutics Inc 1,676.71%$ 1,676.709 millions
Astrotech Corp1,625.00%$ 1,625.000 millions


About Reata Pharmaceuticals Inc Revenue Growth Rates (RETA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Reata Pharmaceuticals Inc (CIK 1358762).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-039225
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Reata Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.